Equities Analysts Set Expectations for EHC Q3 Earnings

Encompass Health Corporation (NYSE:EHC) – Investment analysts at Zacks Research boosted their Q3 2025 EPS estimates for Encompass Health in a research note issued to investors on Wednesday, October 22nd. Zacks Research analyst Team now anticipates that the company will earn $1.18 per share for the quarter, up from their prior estimate of $1.17. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Encompass Health’s current full-year earnings is $4.80 per share. Zacks Research also issued estimates for Encompass Health’s Q4 2025 earnings at $1.28 EPS, FY2025 earnings at $5.22 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.24 EPS, FY2026 earnings at $5.48 EPS, Q1 2027 earnings at $1.45 EPS, Q3 2027 earnings at $1.34 EPS and FY2027 earnings at $5.82 EPS.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, March 16th. The company reported $0.93 earnings per share for the quarter. The business had revenue of $136.30 million during the quarter. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS.

A number of other analysts have also recently commented on the stock. KeyCorp boosted their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. UBS Group boosted their target price on shares of Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Truist Financial boosted their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Bank of America boosted their target price on shares of Encompass Health from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, September 10th. Finally, Weiss Ratings reissued a “buy (b+)” rating on shares of Encompass Health in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $139.86.

Encompass Health Trading Up 1.1%

Shares of Encompass Health stock opened at $126.22 on Thursday. The firm has a 50-day simple moving average of $123.98 and a two-hundred day simple moving average of $117.66. The company has a market cap of $12.71 billion, a P/E ratio of 24.70, a price-to-earnings-growth ratio of 2.18 and a beta of 0.93. Encompass Health has a fifty-two week low of $87.85 and a fifty-two week high of $127.86. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the sale, the executive vice president owned 18,846 shares in the company, valued at approximately $2,329,177.14. This represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.00% of the company’s stock.

Institutional Trading of Encompass Health

A number of hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC raised its holdings in Encompass Health by 23.0% in the 3rd quarter. Global Retirement Partners LLC now owns 449 shares of the company’s stock valued at $57,000 after acquiring an additional 84 shares during the last quarter. Tectonic Advisors LLC raised its holdings in Encompass Health by 1.6% in the 3rd quarter. Tectonic Advisors LLC now owns 5,337 shares of the company’s stock valued at $678,000 after acquiring an additional 82 shares during the last quarter. Braun Stacey Associates Inc. raised its holdings in Encompass Health by 9.3% in the 3rd quarter. Braun Stacey Associates Inc. now owns 223,673 shares of the company’s stock valued at $28,411,000 after acquiring an additional 18,967 shares during the last quarter. Silver Oak Securities Incorporated purchased a new stake in shares of Encompass Health in the 3rd quarter valued at approximately $241,000. Finally, Seascape Capital Management grew its stake in shares of Encompass Health by 8.3% in the 3rd quarter. Seascape Capital Management now owns 26,182 shares of the company’s stock valued at $3,326,000 after buying an additional 2,014 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.